OFI Invest Asset Management Has $95,000 Stock Holdings in Humana Inc. $HUM

OFI Invest Asset Management lifted its holdings in Humana Inc. (NYSE:HUM) by 40.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 390 shares of the insurance provider’s stock after purchasing an additional 112 shares during the quarter. OFI Invest Asset Management’s holdings in Humana were worth $95,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Personalized Indexing Management LLC grew its position in shares of Humana by 33.4% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 14,453 shares of the insurance provider’s stock valued at $3,534,000 after purchasing an additional 3,616 shares during the period. Sivik Global Healthcare LLC boosted its position in Humana by 17.4% during the 2nd quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the insurance provider’s stock worth $6,601,000 after acquiring an additional 4,000 shares during the last quarter. Fifth Third Wealth Advisors LLC boosted its position in Humana by 8.1% during the 2nd quarter. Fifth Third Wealth Advisors LLC now owns 1,337 shares of the insurance provider’s stock worth $327,000 after acquiring an additional 100 shares during the last quarter. Aberdeen Group plc boosted its position in Humana by 30.8% during the 2nd quarter. Aberdeen Group plc now owns 172,161 shares of the insurance provider’s stock worth $41,815,000 after acquiring an additional 40,492 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in Humana by 3.6% during the 2nd quarter. Blue Trust Inc. now owns 1,367 shares of the insurance provider’s stock worth $334,000 after acquiring an additional 48 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Stock Down 3.3%

HUM opened at $270.84 on Tuesday. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $315.35. The stock’s fifty day simple moving average is $279.92 and its 200 day simple moving average is $258.09. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The stock has a market cap of $32.57 billion, a PE ratio of 20.79, a price-to-earnings-growth ratio of 1.64 and a beta of 0.42.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. During the same quarter last year, the company posted $6.96 EPS. The firm’s revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, research analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Friday, September 26th. Humana’s dividend payout ratio is 27.17%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Piper Sandler reduced their price target on Humana from $288.00 to $272.00 and set a “neutral” rating for the company in a research report on Thursday, July 31st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Humana in a research report on Wednesday, October 8th. Barclays reduced their price target on Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a research report on Friday, October 3rd. Robert W. Baird dropped their price objective on Humana from $300.00 to $297.00 and set a “neutral” rating on the stock in a research note on Friday, July 25th. Finally, Wolfe Research upped their price objective on Humana from $283.00 to $313.00 and gave the stock an “outperform” rating in a research note on Monday, October 6th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $298.83.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.